Tedopi, a T-cell epitope-based cancer vaccine, has demonstrated improved overall survival and a better safety profile compared to chemotherapy in HLA-A2 positive patients with advanced or metastatic NSCLC who have progressed after immune checkpoint inhibitors. The Phase 3 trial showed a significant reduction in the risk of death by 41%.
A recent study published in Circulation shows that combining genetic risk with LDL cholesterol levels can accurately predict heart attack risk. The study reveals that individuals with a high polygenic predisposition for heart attack, regardless of their LDL level, are at increased risk.
ABX464 upregulates IL-22 and miR-124, showing strong anti-inflammatory effects in preclinical models. The compound also prevents intestinal inflammation and protects against colitis, with therapeutic effects lasting at least 6 weeks.
The study found that VivoSight OCT significantly improved diagnostic certainty for basal cell carcinoma (BCC) by a factor of four over clinical examination alone, increasing diagnostic accuracy by 50%. The use of OCT also reduced overall biopsies by 36% and correctly diagnosed BCC cases in 87.8% of cases.
Gene Signal's aganirsen shows promise in treating wet age-related macular degeneration and ischemic retinopathy by inhibiting neovascular growth. Clinical studies are scheduled to begin during the second quarter of 2012.
Researchers at Addex Pharmaceuticals have discovered a novel interaction between GLP-1 and GIP receptors, which has the potential to trigger new therapies for Type 2 diabetes. The discovery was made possible by the company's allosteric modulation platform and could lead to the development of orally available small molecule treatments.
Addex Pharmaceuticals highlights the power of its allosteric modulation technology platform, presenting data on nine therapeutic programs across various receptor types and therapeutic areas. The company's technology is allowing it to bring a new kind of chemistry to industrial drug discovery efforts, improving productivity in pharmaceu...
GS-101 demonstrates significant inhibition and regression of corneal neovascularisation in a phase II study. The treatment is generally well-tolerated with no serious side effects, offering a new approach to managing ophthalmic angiogenesis.
A Phase IIa clinical trial shows that ADX10059, a negative mGluR5 allosteric modulator, significantly improves pain-free status and pain improvement in patients with acute migraine attacks. The study's findings support the potential of targeting mGluR5 signaling for migraine prevention.
A Phase IIa clinical trial suggests that targeting glutamate receptor mGluR5 with ADX10059 may prevent migraine attacks before they start. The study found that patients taking ADX10059 were more likely to be pain-free two hours after treatment than those receiving a placebo.
ANG1005, a proprietary peptide vector, transports paclitaxel across the blood-brain barrier with high efficacy. The drug has shown promising results in clinical trials for brain metastasis and malignant glioma, with increased survival rates and reduced tumor growth.
Scientists develop novel strategy to inhibit ß-secretase enzyme in Alzheimer's disease by targeting cell membrane RAFTS. The approach demonstrates effective inhibition of amyloid peptide formation with concentrations as low as 100 nM.